

**In the Claims**

Please add claim 100.

1. (original) An immunostimulatory nucleic acid molecule having at least one internal pyrimidine-purine (YZ) dinucleotide and a chimeric backbone, wherein the at least one internal YZ dinucleotide has a phosphodiester or phosphodiester-like internucleotide linkage, wherein optionally each additional internal YZ dinucleotide has a phosphodiester, phosphodiester-like, or stabilized internucleotide linkage, and wherein all other internucleotide linkages are stabilized.

2. (original) The oligonucleotide of claim 1, wherein the immunostimulatory nucleic acid comprises a plurality of internal YG dinucleotides having a phosphodiester or phosphodiester-like internucleotide linkage.

3. (original) The oligonucleotide of claim 2, wherein every internal YG dinucleotide has a phosphodiester or phosphodiester-like internucleotide linkage.

4. (original) The oligonucleotide of claim 1, wherein the immunostimulatory nucleic acid molecule is any one of SEQ ID NO:1 – 54, SEQ ID NO:55-99 and SEQ ID NO:241, wherein \* shown in the SEQ ID No's in the specification represents phosphorothioate, \_ represents phosphodiester, U represents 2'-deoxyuracil, and 7 represents 7-deazaguanine.

5. (original) The oligonucleotide of claim 1, wherein the immunostimulatory nucleic acid molecule is selected from the group consisting of:

T\*C\_G\*T\*C\_G\*T\*T\*T\_G\*T\*C\_G\*T\*T\*T\_G\*T\*C\_G\*T\*T (SEQ ID NO:100),

T\*C\_G\*T\*C\_G\*T\*T\*T\_G\*T\*C\_G\*T\*T (SEQ ID NO:101),

T\*C\_G\*T\*C\_G\*T\*T\*T\_C\_G\*T\*C\_G\*T\*T (SEQ ID NO:102),

T\*G\*T\*C\_G\*T\*T\*G\*T\*C\_G\*T\*T\_G\*T\*C\_G\*T\*T\_G\*T\*C\_G\*T\*T (SEQ ID NO:103), and

T\*C\_G\*T\*C\_G\*T\*T\*T\*C\*G\*G\*C\*G\*G\*C\*C\*G\*C\*C\*G (SEQ ID NO:104), wherein \* represents phosphorothioate and \_ represents phosphodiester.

6-11. (canceled)

12. (original) The oligonucleotide of claim 1, wherein the at least one internal YG dinucleotide having a phosphodiester or phosphodiester-like internucleotide linkage is CG.

13. (original) The oligonucleotide of claim 1, wherein the at least one internal YG dinucleotide having a phosphodiester or phosphodiester-like internucleotide linkage is TG.

14. (original) The oligonucleotide of claim 1, wherein the immunostimulatory nucleic acid molecule is a B-Class immunostimulatory nucleic acid molecule.

15. (original) The oligonucleotide of claim 1, wherein the immunostimulatory nucleic acid molecule is a C-Class immunostimulatory nucleic acid molecule.

16. (original) The oligonucleotide of claim 1, wherein the immunostimulatory nucleic acid molecule is 4-100 nucleotides long.

17. (original) The oligonucleotide of claim 1, wherein the immunostimulatory nucleic acid molecule is not an antisense oligonucleotide, triple-helix-forming oligonucleotide, or ribozyme.

18-21. (canceled)

22. (original) The oligonucleotide of claim 1 wherein the nucleic acid has a backbone comprising deoxyribose or ribose.

23. (original) The oligonucleotide of claim 1, wherein the oligonucleotide further comprises an adjuvant or a cytokine, or an antigen.

24. (original) The oligonucleotide of claim 1 wherein the phosphodiester or phosphodiester-like internucleotide linkage is phosphodiester.

25. (original) The oligonucleotide of claim 1 wherein the phosphodiester-like linkage is boranophosphonate or diastereomerically pure Rp phosphorothioate.

26. (original) The oligonucleotide of claim 1 wherein the stabilized internucleotide linkages are selected from the group consisting of: phosphorothioate, phosphorodithioate, methylphosphonate, methylphosphorothioate, and any combination thereof.

27. (original) The oligonucleotide of claim 1 wherein the stabilized internucleotide linkages are phosphorothioate.

28. (original) An oligonucleotide comprising:

5’T\*C\*G\*T\*CGTTTGAN<sub>1</sub>CGN<sub>2</sub>\*T\*T3’ (SEQ ID NO: 296)

wherein N<sub>1</sub> is 0-6 nucleotides and optionally is 0-2 nucleotides, wherein N<sub>2</sub> is 0-7 nucleotides, wherein \* refers to the presence of a stabilized internucleotide linkage, and wherein the oligonucleotide includes at least 2 phosphodiester internucleotide linkages and optionally the oligonucleotide is 16-24 nucleotides in length.

29-31. (canceled)

32. (original) An oligonucleotide comprising:

5’ T\*C\*G\*(T\*/A\*)TN<sub>3</sub>CGTTTN<sub>4</sub>CGN<sub>5</sub>\*T\*T 3’ (SEQ ID NO: 301)

wherein N<sub>3</sub> is 0-4 nucleotides, wherein N<sub>4</sub> is 1-5 nucleotides and optionally is 1-2 nucleotide, wherein N<sub>5</sub> is 0-7 nucleotides, wherein \* refers to the presence of a stabilized

internucleotide linkage, and wherein the oligonucleotide includes at least 3 phosphodiester internucleotide linkages and optionally the oligonucleotide is 16-24 nucleotides in length.

33-35. (canceled)

36. (original) An oligonucleotide comprising:

5'T\*C\*G\*T\*C\*GN<sub>N</sub>CGN<sub>NN</sub>C\*G\*N\*C\*G\*T\*T3' (SEQ ID NO: 306)

wherein N is any nucleotide, wherein \* refers to the presence of a stabilized internucleotide linkage, and wherein the oligonucleotide includes at least 3 phosphodiester internucleotide linkages and optionally 5 phosphodiester internucleotide linkages and wherein the oligonucleotide optionally is 16-24 nucleotides in length.

37-38. (canceled)

39. (original) An oligonucleotide comprising:

5'T\*CGCGN<sub>8</sub>CGCGC\*GN<sub>9</sub>3' (SEQ ID NO: 315)

wherein N<sub>8</sub> is between 4 and 10 nucleotides in length and includes at least 1 C\_G motif and optionally at least 2 or 3 CG motifs, wherein N<sub>9</sub> is between 0 and 3 nucleotides in length, wherein \* refers to the presence of a stabilized internucleotide linkage, and wherein \_ refers to the presence of a phosphodiester internucleotide linkage and wherein the oligonucleotide has a length of 15-40 nucleotides.

40-43. (canceled)

44. (original) An oligonucleotide comprising:

5'T\*C\_G(N<sub>6</sub>C\_G N<sub>7</sub>)<sub>2-3</sub>T\*C\_G\*T\*T3' (SEQ ID NOs: 311-312)

wherein N<sub>6</sub> and N<sub>7</sub> are independently between 1 and 5 nucleotides in length, and optionally N<sub>6</sub> is one nucleotide, preferably T or A and optionally N<sub>7</sub> is five nucleotides, preferably five pyrimidines or TTTTG wherein \* refers to the presence of a stabilized

internucleotide linkage, and wherein \_ refers to the presence of a phosphodiester internucleotide linkage and wherein the oligonucleotide has a length of 16-40 nucleotides.

45. (canceled)

46. (original) An oligonucleotide comprising:

5'T\*T\*GX<sub>1</sub>X<sub>2</sub>TG X<sub>3</sub>X<sub>4</sub>T\*T\*T\*T\*N<sub>10</sub>T\*T\*T\*T\*T\*T3' (SEQ ID NO: 18)

wherein N<sub>10</sub> is between 4 and 8 nucleotides in length and includes at least 1 C\_G motif and optionally includes at least 2 or 3 CG motifs, wherein X<sub>1</sub>, X<sub>2</sub>, X<sub>3</sub> and, X<sub>4</sub> are independently C or G, wherein \* refers to the presence of a stabilized internucleotide linkage, and wherein \_ refers to the presence of a phosphodiester internucleotide linkage and wherein the oligonucleotide has a length of 24-40 nucleotides.

47. (canceled)

48. (original) An oligonucleotide comprising:

5' T\*C\*G\*C\_G\*A\*C\*G\*T\*T\*C\_G\*G\*C\*G\*C\_G\*C\*G\*G\*C\*C\*G 3' (SEQ ID NO: 321)

wherein \* refers to the presence of a stabilized internucleotide linkage, and wherein \_ refers to the presence of a phosphodiester internucleotide linkage and optionally wherein the oligonucleotide has a length of 21-40 nucleotides.

49. (original) An oligonucleotide comprising:

an octameric sequence comprising at least one YZ dinucleotide having a phosphodiester or phosphodiester-like internucleotide linkage, and at least 4 T nucleotides, wherein Y is a pyrimidine or modified pyrimidine, wherein Z is a guanosine or modified guanosine, and wherein the oligonucleotide includes at least one stabilized internucleotide linkage.

50-65. (canceled)

66. (original) An oligonucleotide comprising:

5' TCGTCGTTTGACGTTTGTCTT 3' (SEQ ID NO: 368)

wherein at least one CG dinucleotide has a phosphodiester or phosphodiester-like internucleotide linkage, and the oligonucleotide includes at least one stabilized internucleotide linkage.

67. (original) An oligonucleotide comprising:

5'GNC 3', wherein N is a nucleic acid sequence of 4-10 nucleotides in length and is at least 50% T and does not include a CG dinucleotide, and the oligonucleotide includes at least one stabilized internucleotide linkage.

68-69. (canceled)

70. (previously presented) A method for modulating an immune response, comprising administering to a subject an oligonucleotide of claim 1, in an effective amount to modulate an immune response.

71-87. (canceled)

88. (original) A method for treating airway remodeling, comprising: administering to a subject an oligonucleotide comprising a CG dinucleotide, in an effective amount to treat airway remodeling in the subject.

89-93. (canceled)

94. (original) A method for stimulating an immune response, comprising administering to a subject an oligonucleotide of at least 5 nucleotides in length in an effective amount to stimulate an immune response, wherein the oligonucleotide includes at least one immunostimulatory dinucleotide motif wherein the internucleotide linkage between the

nucleotides of the dinucleotide has R chirality and wherein at least 70% of the other internucleotide linkages of the oligonucleotide have S chirality.

95. (previously presented) An oligonucleotide, comprising: an immunostimulatory nucleic acid molecule comprising a chimeric backbone and at least one sequence N<sub>1</sub>YGN<sub>2</sub>, wherein independently for each sequence N<sub>1</sub>YGN<sub>2</sub> YG is an internal pyrimidine-guanosine (YG) dinucleotide, N<sub>1</sub> and N<sub>2</sub> are each, independent of the other, any nucleotide, and wherein for the at least one sequence N<sub>1</sub>YGN<sub>2</sub> and optionally for each additional sequence N<sub>1</sub>YGN<sub>2</sub>:


the YG dinucleotide has a phosphodiester or phosphodiester-like internucleotide linkage, and

(a) N<sub>1</sub> and Y are linked by a phosphodiester or phosphodiester-like internucleotide linkage when N<sub>1</sub> is an internal nucleotide,

(b) G and N<sub>2</sub> are linked by a phosphodiester or phosphodiester-like internucleotide linkage when N<sub>2</sub> is an internal nucleotide, or


(c) N<sub>1</sub> and Y are linked by a phosphodiester or phosphodiester-like internucleotide linkage when N<sub>1</sub> is an internal nucleotide and G and N<sub>2</sub> are linked by a phosphodiester or phosphodiester-like internucleotide linkage when N<sub>2</sub> is an internal nucleotide, wherein all other internucleotide linkages are stabilized.

96. (previously presented) An oligonucleotide comprising




wherein N<sub>1</sub> and N<sub>3</sub> are each independently a nucleic acid sequence 1-20 nucleotides in length, wherein \_ indicates an internal phosphodiester or phosphodiester-like internucleotide linkage, wherein N<sub>2</sub> is independently a nucleic acid sequence 0-20 nucleotides in length, and wherein G-N<sub>2</sub>-C includes 1 or 2 stabilized linkages.

97. (previously presented) An oligonucleotide comprising



wherein N<sub>1</sub> and N<sub>3</sub> are each independently a nucleic acid sequence 1-20 nucleotides in length, wherein \_ indicates an internal phosphodiester or phosphodiester-like internucleotide linkage, wherein N<sub>2</sub> is independently a nucleic acid sequence 4-20 nucleotides in length, and wherein G-N<sub>2</sub>-C includes at least 5 stabilized linkages.

98. (previously presented) An oligonucleotide comprising



wherein N<sub>1</sub>, N<sub>2</sub>, and N<sub>3</sub> are each independently a nucleic acid sequence of 0-20 nucleotides in length and wherein \_ indicates an internal phosphodiester or phosphodiester-like internucleotide linkage, wherein the oligonucleotide is not an antisense oligonucleotide, triple-helix-forming oligonucleotide, or ribozyme.

99. (previously presented) An oligonucleotide comprising



wherein N<sub>1</sub> and N<sub>2</sub> are each independently a nucleic acid sequence of 0-20 nucleotides in length, wherein n=2 or n=4-6, wherein X<sub>1</sub> and X<sub>2</sub> are each independently a nucleic acid sequence having phosphorothioate internucleotide linkages of 3-10 nucleotides, wherein N<sub>1</sub>-(GTCGTT)<sub>n</sub>-N<sub>2</sub> includes at least one phosphodiester internucleotide linkage, and wherein 3' and 5' nucleotides of the oligonucleotide do not include a poly-G, poly-A, poly-T, or poly-C sequence.

100. (new) The oligonucleotide of claim 44, wherein the oligonucleotide has the following structure: 5' T\*C\_G\*T\*C\_G\*T\*T\*T\*T\*G\*A\*C\_G\*T\*T\*T\*T\*G\*T\*C\_G\*T\*T 3' (SEQ ID NO: 313) or 5' T\*C\_G\*A\*C\_G\*T\*T\*T\*T\*G\*T\*C\_G\*T\*T\*T\*T\*G\*T\*C\_G\*T\*T 3' (SEQ ID NO: 314).